Dong Pei | Urology | Sun Yat-sen University Cancer Center-Sun Yat-sen University Cancer Center

Name: Dong Pei

Title: Professor

Email: dongpei@sysucc.org.cn

Phone:

share

Profile

Committed to the surgical management and multidisciplinary treatment of complex renal cell carcinoma, serving as the attending professor for renal cell carcinoma.

Specializes in renal cancer surgery, with outstanding expertise in robot-assisted nephron-sparing surgery, particularly tubeless robotic partial nephrectomy. Has completed more than 1,000 robot-assisted surgeries, and the annual surgical volume has consistently ranked among the top in the department.

As the principal investigator, increased the 5-year survival rate of patients with advanced renal cell carcinoma from 20% to 57%, and prolonged survival in patients with local recurrence after nephrectomy from 45.7 months to 71 months.

Representative works published in Clinical Cancer Research, Clinical and Translational Medicine, Journal of Advanced Research, International Journal of Cancer, etc.

As a project leader, led one nationally leading innovative surgical technique for renal cancer and seven single-/multi-center prospective clinical trials, supported by the National Natural Science Foundation of China and the Guangdong Natural Science Foundation.

Interests

The comprehensive treatment for renal cell carcinoma, including: surgical treatment, radiotherapy, interventional therapy, targeted therapy, immunotherapy, and corresponding basic research.

Education

9/2005 –7/2009: M.D in surgery, XiangYa Medical College, Central South University

Research area: Genitourinary cancer research

1/2008-1/2009: Joint Training Ph.D, Harvard Medical School

Research area: Genitourinary cancer research

Publications

1. Dong P, Zhang X, Peng Y, Zhang Y, Liu R, Li Y, Pan Q, Wei W, Guo S, Zhang Z, Han H, Zhou F, Liu Y, He L. Genomic Characteristics and Single-Cell Profiles After Immunotherapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma. Clin Cancer Res. 2022 Nov 1;28(21):4807-4819.

2. Peng YL, Yu B, Huang TX, Zhou ZH, Zhang H, Tang WXF, Xu XX, Zhu DQ, Yang RW, Bao H, Wu X, Han H, Zhang ZL, He LR, Dong P, Wei WS. Early detection of renal cell carcinoma: a novel cell-free DNA fragmentomics-based liquid biopsy assay. ESMO Open. 2025 Jul;10(7):105323.

3. Huang T, Peng Y, Liu R, Ma B, Chen J, Wei W, Zhong W, Liu Y, Guo S, Han H, Zhou F, Zhang Z, He L, Dong P. Prognostic significance of immune evasion-related genes in clear cell renal cell carcinoma immunotherapy. Int Immunopharmacol. 2024 Dec 5;142(Pt B):113106.

4. Huang T, Wang J, Liu R, Wei W, Liu Y, Zhang Z, Guo S, Han H, Zhou F, He L, Dong P. Safety and Efficacy of Second-Line TKI Plus Anti-PD1 in Metastatic Non-Clear Cell Renal Cell Carcinoma: A Real-World Study. Clin Genitourin Cancer. 2024 Apr;22(2):252-260.e3. doi: 10.1016/j.clgc.2023.11.007. Epub 2023 Nov 19. Erratum in: Clin Genitourin Cancer. 2025 Feb;23(1):102247.

5. Li Y, Zheng R, Zhang Y, Huang C, Tian L, Liu R, Liu Y, Zhang Z, Han H, Zhou F, He L#, Dong P#. 68Ga-PSMA-11 PET/CT for evaluating primary and metastatic lesions in different histological subtypes of renal cell carcinoma. Int J Cancer. 2022 Jun 25.

6. Qian Long, Chunyu Huang, Jinsheng Huang, Qi Meng, Yanjun Cheng, Yilin Li, Liru He, Miao Chen, Changlin Zhang, Xiaonan Wang, Wancui Zhu, Jin Peng, Dingbo Shi, Fufu Zheng, Pei Dong#, Wuguo Deng#. Prognostic value of JAK3 promoter methylation and mRNA expression in clear cell renal cell carcinoma. Journal of Advanced Research, 2021.

7. Ning K, Li Z, Liu H, Tian X, Wang J, Wu Y, Xiong L, Zou X, Peng Y, Zhou Z, Zhou F, Yu C, Luo J, Zhang H, Dong P#, Zhang Z. Perirenal Fat Thickness Significantly Associated with Prognosis of Metastatic Renal Cell Cancer Patients Receiving Anti-VEGF Therapy. Nutrients. 2022 Aug 18;14(16):3388.

8. Long Q, He L, Peng J, Meng Q, Zhang C, Chen M, Wang X, Zhu W, Zheng F, Dong P#, Deng W#. Prognostic, clinicopathological, and immune correlation of NLRP3 promoter methylation in kidney renal clear cell carcinoma. Clin Transl Med. 2021 Oct;11(10):e528.

9. Zhang Z#, Xiong L, Wu Z, Liu H, Ning K, Peng Y, Yu C, Ding Y, Weng D, Xia J, Jiang L, Guo S, Han H, Zhou F, Dong P#. Neoadjuvant combination of pazopanib or axitinib and programmed cell death protein-1-activated dendritic cell-cytokine-induced killer cells immunotherapy may facilitate surgery in patients with renal cell carcinoma. Transl Androl Urol. 2021 May;10(5):2091-2102.

Our Experts